Skyline Therapeutics Presents Late-Breaking Abstract on SKG1108, a Novel Optogenetic Gene Therapy for Retinitis Pigmentosa, at ASGCT 2025
SHANGHAI, May 10, 2025 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven clinical-stage gene therapy company focused on developing unique and novel solutions for rare and severe diseases, today announced a late-breaking abstract presentation on SKG1108, its investigational optogenetic gene therapy for Retinitis Pigmentosa (RP), at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting (May 13–17, 2025, New Orleans, Louisiana).
ASGCT 2025 Late-Breaking AbstractAbstract Title: SKG1108: Optogenetic Gene Therapy with AAV-BWLP for Visual Restoration in Retinitis Pigmentosa via a Single Intravitreal InjectionAbstract No.：2023Date & Time: May 13, 2025 | 6:00 PM – 7:30 PM CT
About SKG1108SKG1108 is an optogenetic adeno-associated virus (AAV) gene therapy vector designed to restore vision in RP patients with photoreceptor degeneration. Its novel design combines a proprietary intravitreal capsid and a uniquely engineered Broad Wavelength Light-sensing Protein (BWLP) comprising opsins of multiple sources, which demonstrated strong and broad wave-length range light-responsive activity in in vitro electrophysiological studies. In in vivo studies, a single intravitreal injection of SKG1108 showed superior efficacy and safety in rd1 mice, with striking functional improvements in visual pathway electrophysiology, light perception and visual acuity behavioral tests. The therapy delivers a single-stranded DNA payload encoding light-activatable proteins to the retina, bypassing the need to target specific genetic mutations. By generating new photo-sensing cells, SKG1108 aims to restore visual function in late-stage RP patients, regardless of their underlying genetic defect. SKG1108 received U.S. FDA Orphan Drug Designation (ODD) in September 2024.
About Retinitis Pigmentosa (RP)Retinitis Pigmentosa (RP) is a type of inherited retinal diseases (IRDs) linked to mutations in over 100 different genes, leading to progressive vision loss that typically begins with night blindness (rod degeneration), followed by tunnel vision and eventual legal blindness due to near-total photoreceptor death (rod and cone degeneration). Currently, no effective treatments worldwide can effectively slow, halt, or reverse photoreceptor degeneration, and existing gene-specific therapies only apply to a small subset of RP patients. SKG1108's mutation-agnostic optogenetic approach—designed to restore vision independent of genetic defects—has the potential to become a transformative treatment for the vast majority of RP patients, including those with advanced disease.
About Skyline TherapeuticsSkyline Therapeutics is an innovation-driven, clinical-stage gene therapy company focused on developing unique and novel therapeutic solutions for rare and severe diseases with high unmet needs. Leveraging our cutting-edge adeno-associated virus (AAV) platform, which encompasses multiple proprietary technologies for capsid discovery, vector design and engineering, process development and GMP manufacturing, we are advancing a diverse pipeline of gene therapies targeting ocular, neurological, and cardiovascular disorders. Our lead programs are rapidly progressing through clinical trials with regulatory approvals and special designations from the US FDA and China NMPA, bringing us closer to providing life-changing therapies to patients in need. www.skytx.com
About ASGCTThe American Society of Gene & Cell Therapy (ASGCT) is a professional non-profit medical and scientific organization dedicated to the understanding, development and application of gene, related cell and nucleic acid therapies, as well as promotion of professional and public education in the field. With more than 5,000 members in the US and worldwide, ASGCT is the largest association of individuals involved in gene and cell therapy research. The ASGCT Annual Meeting is the premier event for gene and cell therapy professionals to learn from the latest scientific research and stay current on new technologies.
View original content:https://www.prnewswire.com/news-releases/skyline-therapeutics-presents-late-breaking-abstract-on-skg1108-a-novel-optogenetic-gene-therapy-for-retinitis-pigmentosa-at-asgct-2025-302451661.html
SOURCE Skyline Therapeutics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
16 minutes ago
- Wall Street Journal
Colonoscopies Beat the Alternative Every Day
I read Jim Sollisch's complaints about the discomfort of colonoscopy preparation with amusement and concern ('Colonoscopy Prep Is Worse Than IKEA,' op-ed, June 3). I have had 12 colonoscopies since I was 50 thanks to a family history of colon cancer. The prep is uncomfortable and inconvenient. The alternative is far worse. My father was diagnosed with this terrible cancer in 1958. Doctors gave him six months to live in a time before colostomies were common. He lasted five years—a time I cherish—but the cost to him was high. I think watching someone die from colon cancer might help Mr. Sollisch put the prep into perspective. It isn't as unbearable as he describes, and I would never want to see anyone decline a procedure for one of the most preventable cancers. If you are at risk for colon cancer, schedule your procedure today. Ken Gurak
Fast Company
17 minutes ago
- Fast Company
1 in 5 people are having fewer children due to fear of the future: UN
Falling fertility rates typically get blamed on the women of the world. But a new study published by the United Nations Population Fund (UNFPA) says both men and women 'face significant barriers to realizing their fertility aspirations.' It's not that they don't want to have children—rather, they just aren't able to in the ways they want to. According to the report, barriers in political discourse, healthcare policies, financial instability, and climate change are some of the leading causes for globally declining birth rates, and furthermore, they prevent many from realizing their preferred child status. 'The evidence is clear: We are moving from a world of rapid population expansion, in the mid-20th Century, to a period of declining fertility rates,' Dr. Natalia Kanem, Executive Director of UNFPA said. UNFPA partnered with YouGov to ask 14,000 people across 14 countries what they want for their reproductive futures and why. According to the report, nearly 1 in 5 participants cited fears of the future affecting their decisions to have fewer children than desired, including concerns about climate change, environmental degradation, wars, and pandemics. Meanwhile, 39% reported financial limitations affecting their decisions. The countries included in the study represent a third of the world population, and include North Korea (the country with the lowest fertility rate), Nigeria (the country with the highest fertility rate), and the U.S. (somewhere in the middle). All participants' reasons behind their reproductive status were divided into five factors: Health, including infertility and a lack of medical care Economic, including unemployment and housing situations Changed desires, including partner or personal decisions Concerns over future, including political or climate concerns Other, including lack of partner or societal pressure 'It is hard to escape the conclusion that these concerns—which certainly warrant policy responses—are rooted in outdated notions around who should be reproducing and why, and the notion that the achievement of a country's preferred birth rate will ensure economic and political security,' Dr. Kanem said.
CBS News
23 minutes ago
- CBS News
Chesapeake Bay watershed health declined in 2024, report shows
The Chesapeake Bay declined in health in 2024, according to an annual report published by the University of Maryland Center for Environmental Science (UMCES). During the annual assessment, officials look at the ecological, societal and economic indicators. The report, which uses data from 2024, gave the Bay a C grade, while watershed health was given a C+ grade. The C grade was a five-point decrease compared to 2023. Despite the decline in health in 2024, the Bay has shown long-term improvements over the last couple of decades, the report shows. Chesapeake Bay health declined in 2024 UMCES looked at seven bay indicators and 12 watershed indicators to grade the health of the waterways. According to the report, the bay indicators, like nitrogen levels, oxygen levels and water clarity, are used to assess the health of the aquatic ecosystem, while watershed indicators look at external factors like protected lands in the area, job growth and temperatures. UMCES said the decrease in score is not surprising due to the weather conditions in 2024. According to the report, 2024 was the hottest year on record, with extreme rainfall patterns. Parts of the watershed experienced drought with short, intense bursts of rainfall that caused runoff. "These downpours can cause water to flow over the ground rather than soak into it, increasing the fertilizer, dirt and debris carried into waterways," the report said. Despite the decreased 2025 score, the Bay has shown improvements since the 1980s, according to the report. According to the report, six regions - including Elizabeth, James, Patapsco and Back Rivers, Upper Western Shore, Upper Bay and Lower Bay - have shown long-term improvements. The Upper Eastern Shore was the only region to show declining trends. The Chesapeake Bay declined in health in 2024, according to an annual report published by the University of Maryland Center for Environmental Science (UMCES). University of Maryland Center for Environmental Science Some indicators, like dissolved oxygen and total nitrogen levels, have also shown long-term improvements, while chlorophyll a and water clarity scores have declined, the report shows. UMCES attributed the improvements to management and restoration efforts, including upgraded wastewater treatment plants, reduced nutrient and sediment, seagrass restoration and oyster plantings. "This year's report underscores the importance of continued investment and highlights the progress we've made over the last decade," said Dr. Fernando Miralles-Wilhelm, President of UMCES. Chesapeake Bay freshwater gets saltier With more than 100,000 miles of streams and millions of acres of lakes and reservoirs, the Chesapeake Bay region provides drinking water, resources for farmers and power. In its 2025 report, UMCES determined that the Chesapeake Bay's freshwater is becoming more salty due to an issue called freshwater salinization. The change is caused by rainfall patterns, drought, rises in sea level and human activities. The report shows freshwater salinization is expected to get worse as the population in the area increases and the environment continues to change. The report recommends switching to eco- and pet-friendly salt during the winter and using less de-icing product on roads and sidewalks. Baltimore waterways show declining water quality In May, a similar study from non-profit Blue Water Baltimore found that the water quality at the Inner Harbor and surrounding watershed has declined in the past decade. According to the report, water quality at the Baltimore Harbor, Gwynn Falls and the Patapsco River regions has declined between 2013 and 2024. Water quality in the Jones Falls region slightly improved. The report detailed that chlorophyll levels were poor in most areas, while bacteria levels and dissolved oxygen levels improved.
